Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risdiplam in non-ambulant type 2 and 3 spinal muscular atrophy (Japan, double-blind, placebo-controlled)
jRCT2080223666Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in spinal muscular atrophy type 2 (SMA2) and Spinal muscular atrophy type 3 (SMA3) comparing Risdiplam with Placebo (2 arms). Started Oct 2017; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy type 2 (SMA2)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on jRCT2080223666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223666.